New switches support growing SMB, MSP, and enterprise network requirements with 10G aggregation, 100G backbone scalability, interoperable Layer 3 routing, resilient design, and cloud visibility with local control.
COSTA MESA, Calif., July 16, 2026 /PRNewswire/ -- EnGenius today announced a new lineup of cloud-managed Layer 3 switches purpose-built for enterprise, system integrator, VAR, and MSP networks.
The new series includes three models: the enterprise-class ECS8830F and ECS8854F, along with the ECS6824F for SMB core, branch, and managed service provider (MSP) deployments. Together, the EnGenius Cloud-Managed Layer 3 Switches help organizations modernize network infrastructure with high-density 10G aggregation, 100G backbone connectivity, advanced Layer 3 routing, resilient design, and centralized cloud-based management across access, aggregation, and core.
As enterprise networks support more Wi-Fi 7 deployments, video analytics, edge applications, virtualized workloads, distributed services, and high-bandwidth east-west traffic, the network core can no longer be treated as a simple aggregation point. Modern IT teams need a core architecture that supports scalable routing, secure segmentation, operational resilience, and clear visibility across the network.
Enterprise-Class Core and Aggregation: ECS8830F and ECS8854F
The ECS8830F and ECS8854F are built for enterprise core and aggregation networks that require advanced Layer 3 routing, high availability, and scalable network operations.
The ECS8830F provides 24 × 10G SFP+ ports and 6 × 100G QSFP28 uplinks with up to 1.68 Tbps switching capacity, while the ECS8854F expands scale with 48 × 10G SFP+ ports and 6 × 100G QSFP28 uplinks with up to 2.16 Tbps switching capacity. Both platforms support up to 600 Mpps forwarding performance and wire-speed throughput to support high-performance enterprise network environments.
To support scalable network architectures, the platforms combine advanced Layer 3 routing and network virtualization capabilities, including OSPFv2/v3, BGP/BGP4+, IS-IS, ECMP, VRRP, Policy-Based Routing (PBR), BFD, and VXLAN EVPN. These capabilities enable resilient traffic forwarding, network segmentation, high-availability designs, and scalable multi-site connectivity while supporting interoperability across existing infrastructure investments. The result is simplified network operations, improved resiliency, and the flexibility to scale enterprise networks as business requirements evolve.
For maximum network resiliency and business continuity, the platforms support MC-LAG and VSF, along with 1+1 redundant hot-swappable power supplies and 3+1 redundant hot-swappable fan modules. This architecture eliminates single points of failure, enables seamless failover, and maintains service continuity, reducing service disruption and simplifying maintenance for enterprise network environments.
The series also supports a hybrid operational model. IT teams can use EnGenius Cloud for centralized visibility and monitoring while retaining local access through Web UI, CLI, SNMP, NETCONF, syslog, and related operational tools for configuration, troubleshooting, and day-to-day administration.
Right-Sized 10G Layer 3 Core for SMB and MSP Networks: ECS6824F
The ECS6824F delivers a high-performance 10G Layer 3 fiber core to growing SMBs, branch networks, and MSP-managed environments seeking greater scalability, security, and network control without the complexity of enterprise-class core platforms.
The 1U switch provides 24 × 10G SFP+ ports and 480 Gbps switching capacity, with Static Routing, RIP, and OSPFv2/v3 to help organizations segment departments, applications, surveillance systems, guest networks, and server zones more effectively.
For video-centric and multicast environments, the ECS6824F includes IGMP and MLD support to improve multicast traffic efficiency for IPTV and IP surveillance deployments. It also integrates core-layer security controls, including 802.1X authentication, ACLs, DHCP Snooping, IP Source Guard, ARP protection, Port Security, Storm Control, and DoS protection.
Dual internal power supplies add hardware resiliency, while EnGenius Cloud delivers centralized visibility, monitoring, and management for IT teams and MSPs.
Extending the EnGenius Portfolio from Access to Core
"This launch represents a significant expansion of the EnGenius networking portfolio and marks an important step in extending our cloud-managed platform from access to core," said Roger Liu, CEO of EnGenius. "As enterprise networks continue to evolve, organizations need switching solutions that deliver greater scalability, resiliency, and operational simplicity. With this new series, we are providing a stronger foundation to support modern enterprise and managed network deployments."
With the introduction of the new series, EnGenius extends its cloud-managed switching portfolio to address enterprise core, aggregation, and SMB core deployments. Together with EnGenius Cloud, the new switches combine cloud visibility with local control, enabling organizations, system integrators, VARs, and MSPs to deploy and manage networks through a consistent operational experience as their infrastructure grows.
Learn more about Cloud-Managed Layer 3 Switching Portfolio
ECS6824F: https://www.engeniustech.com/ecs6824f-cloud-managed-layer-3-fiber-switch.html
ECS8830F: https://www.engeniustech.com/ecs8830f-layer-3-stackable-switch.html
ECS8854F: https://www.engeniustech.com/ecs8854f-48-port-stackable-layer-3-switch.html
About EnGenius
EnGenius Technologies is a global leader in cloud-driven networking solutions, with over 25 years of expertise in developing and delivering innovative, user-friendly hardware and software. The company's secure, cloud-managed ecosystem — including wireless access points, network switches, VPN Firewalls, AI cameras, AI-powered network video systems, and power distribution units — empowers businesses across industries such as enterprise, education, healthcare, retail, and logistics to build high-performance, reliable, and scalable network infrastructures.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
EnGenius Strengthens Cloud-Managed Layer 3 Switching Portfolio with New Core and Aggregation Switches
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue
PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.
The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine.
GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability.
"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery."
First-Half 2026 Highlights
GenScript Life Science Group
- Revenue of approximately US$319.0 million, up 28.8%
- Adjusted gross profit of approximately US$184.5 million, up 46.1%
- Adjusted operating profit of approximately US$94.0 million, up 102.8%
- Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine
AI-Enabled Drug Discovery
- AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period
- Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem
ProBio
- Revenue increased 34.2% on a comparable basis to approximately US$61.1 million
- New orders increased 54%
- Adjusted operating loss narrowed 22.5% to US$24.3 million
- Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027
Bestzyme
- Revenue of approximately US$30.4 million, up 7.4%
- Adjusted gross profit of approximately US$13.0 million, up 14.0%
Integrated Capabilities Support Growth Across the Portfolio
The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow.
GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers.
To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex.
Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development.
Outlook
GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses.
The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation.
Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website.
About GenScript Biotech Corporation
Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com.
Investor and Media Contacts
Investor Relations
Email: ir@genscript.com
Media Contact
Kate Grusich, Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
